Biopharma Excellence partners with biopharmaceutical companies on their journeys to develop and deliver scientific advances and product breakthroughs. The Biopharma Excellence worldwide team of subject matter experts—comprising scientists, specialists in cell and gene therapies, vaccines, monoclonal antibodies, process development, and former regulators—has a verifiably successful record of developing solutions to the kinds of scientific, regulatory, and commercialization challenges unique to biopharmaceutical companies. We devise global solutions while grounded in the major regulatory markets within Europe, the United States, and Australia. Together we deliver your vision.
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the global voice of the sector, representing the interests of 380+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visit www.alliancerm.org.